OncoMatch/Clinical Trials/NCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Is NCT06136650 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for metastatic castration-resistant prostate cancer (mcrpc).
Treatment: Opevesostat · Dexamethasone · Fludrocortisone acetate · Hydrocortisone · Abiraterone acetate · Prednisone acetate · Enzalutamide — The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease shown by computed tomography (CT)/magnetic resonance imaging (MRI)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: next-generation hormonal agent — hormone sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC)
disease that progressed during or after treatment with one next-generation hormonal agent (NHA) for hormone sensitive prostate cancer (HSPC) (metastatic hormone-sensitive prostate cancer [mHSPC] or non-metastatic hormone-sensitive prostate cancer [nmHSPC]), or castration-resistant prostate cancer (CRPC) (metastatic castration-resistant prostate cancer [mCRPC] or non-metastatic castration-resistant prostate cancer [nmCRPC]), for at least 8 weeks of NHA treatment (at least 14 weeks of NHA treatment for participants with bone progression)
Cannot have received: taxane-based chemotherapy for metastatic castration-resistant prostate cancer
Has received a taxane-based chemotherapy for metastatic castration-resistant prostate cancer (mCRPC)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Arizona Cancer Center - North Campus ( Site 0073) · Tucson, Arizona
- UCLA Hematology/Oncology - Santa Monica ( Site 0044) · Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) · Orange, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center (0120) · Orange, California
- Stanford Cancer Center ( Site 0036) · Palo Alto, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06136650 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane-based chemotherapy for metastatic castration-resistant prostate cancer disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages